Why to Replace an ACE  or ARB With an ARB/Neprilysin Inhibitor?

In the 2016 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) Focused Update on New Pharmacological Therapy for Heart Failure(1), there is a new recommendation: in patients with chronic symptomatic heart failure with reduced ejection fraction New York Heart Association functional class II or III who tolerate an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, replacement by an ARNI is recommended to further reduce morbidity and mortality, where ARNI stands for Valsartan/Sacubitril (Novartis Pharmaceuticals, East Hanover, New Jersey), an angiotensin-receptor/neprilysin inhibitor.
Source: Journal of the American College of Cardiology - Category: Cardiology Source Type: research